Strategic partnerships Biosplice is actively engaging with larger pharmaceutical players such as Novo Nordisk on a pre-clinical collaboration to leverage DYRK inhibition for diabetes, presenting a clear path for co-development and licensing conversations with potential partners in endocrinology and metabolic diseases.

Internal pipeline Beyond LOR for knee osteoarthritis, Biosplice through its affiliate TenaRx is pursuing diabetes, oncology, and neurology programs, signaling opportunities to cross-sell services, platform capabilities, and diagnostic or profiling assets to interested drug developers.

Clinical collaboration Recent DoD-supported neurology collaboration and Roskamp Institute engagement indicate a readiness to partner on neurology programs, offering sales angles around research funding alignment, translational capabilities, and joint development for CNS indications.

Phase readiness LOR’s progression through a robust clinical development program with demonstrated pain, function, and joint space outcomes, despite not yet FDA-approved, creates a window for clinical services, companion diagnostics, or investigatorアクセス for CRO partnerships and trial support.

Financial and scale signals Historical financing activity and recent partnerships, coupled with modest revenue levels, suggest a need for scalable collaboration, licensing, or co-development deals with cost-sharing structures to accelerate growth and expand technology adoption in smaller biotech ecosystems.